Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer’s Disease

Overview

This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.

Full Title of Study: “Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer’s Disease: A Multi-center Single-arm Study in China”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2019

Detailed Description

This study is a multi-center, single-arm, open labeling clinical trial, which the objective is to evaluate the safety and Efficacy of donepezil in Alzheimer's disease( AD) patients in China, and investigate the relationship between Apo-E gene type with adverse events of donepezil.

Interventions

  • Drug: Donepezil
    • Eligible patients is treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d,the patient can reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who cannot endure the 10mg/d titration of 2nd time and then back to 5mg/d or discontinuance of Aricept® should be regarded as to quit the study. There will be a visting at week 0, the end of week 4 and the end of week 20 ,respectively.

Arms, Groups and Cohorts

  • Other: donepezil
    • This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer’s disease in China.

Clinical Trial Outcome Measures

Primary Measures

  • Monitoring and recording the count and incidence of adverse events (AEs)
    • Time Frame: 20 weeks
    • To evaluate the safety and tolerability of donepezil for up to 20 weeks in mild to moderate Alzheimer’s disease( AD) patients.

Secondary Measures

  • Monitor and record the number of patients withdrew from trial for adverse events
    • Time Frame: 20 weeks
    • To evaluate the safety and tolerability of donepezil for up to 20 weeks in mild to moderate AD patients by recording incidence of withdraw in each type adverse events.
  • Change from baseline to 20 weeks in MMSE scores
    • Time Frame: Baseline, 4, 20 weeks
    • To evaluate the efficacy of Donepezil with titration on cognitive function measured the change scores of mini-mental state examination (MMSE) at 4 weeks and 20 weeks in mild to moderate AD patients.
  • Change from baseline to 20 weeks in ADL scores
    • Time Frame: Baseline, 4, 20 weeks
    • To evaluate the efficacy of Donepezil with titration for on activities of daily living measured the scores of Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) inventory at 4 weeks and 20 weeks in mild to moderate AD patients.
  • Correlation analysis between Apo-E genotyping and adverse events of donepezil
    • Time Frame: 4 weeks
    • To detect and analyze the Apo-E genotyping using the blood sample obtained in Visting 2 at the end of week 4.

Participating in This Clinical Trial

Inclusion Criteria

1. 50 ≤ years of age < 85years. 2. Patients newly diagnosed as probable AD based on NINCDS- ADRDA (1984); Mild to moderate AD with MMSE10-24, modified Hachinski ischaemic scale (MHIS)≤4, ADL≥23,HAMD<7. 3. MRI image supports the diagnosis of AD (medial temporal lobe atrophy, Fazekas scale of white matter lesions≤2). 4. 5mg daily of Donepezil for at least four weeks before enrollment. 5. Patient with exclusive caregiver. 6. Move freely with or without walking aid. 7. With good eyesight and hearing, can cooperate with the examination and treatment. 8. Patient and caregiver who signed the written informed consent form for the terms of personal and medical information. Exclusion Criteria:

1. With Vascular dementia or other types of dementia. Accompanied by other psychiatric or neurological disorders (e.g. delirium, depression, Parkinson's disease, etc). 2. With type I diabetes, obstructive lung disease or asthma, vitamin B12 or folic acid deficiency, thyroid dysfunction, severe liver or kidney dysfunction, severe cardiac insufficiency (congestive heart-failure, myocardial infarction, Sick Sinus Syndrome, II-III degree atrioventricular block or heart rate<50bpm). 3. Epilepsy or head trauma resulted in unconsciousness once occured in the past two years. 4. Blood diseases (such as anemia, granulocytes, leukemia, etc) or tumor 5. With Hematologic Disease or neoplasms within past 2 years. 5. Has a history of alcohol dependence and drug abuse. 6. With known hypersensitivity to medicines or foods. 7. Taking anticholinergic agents or antihistaminic agents. 8. Patients who had been hospitalized continuously for more than 3 months before screening.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Friendship Hospital
  • Collaborator
    • Eisai China Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jianping Jia, Director of Neurology Department – Beijing Friendship Hospital
  • Overall Official(s)
    • Cuibai Wei, MD,PhD, Study Director, Dept of Neurology, Beijing Friendship Hospital, Capital Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.